Definitions**Nosocomial pneumonia:** Hospital‐acquired pneumonia starting at least 48 to 72 hours after admission.**Aspiration pneumonia:** Lung infection caused by inhalation of oropharyngeal secretions that are colonized with pathogenic bacteria.**Aspiration pneumonitis:** Chemical injury to lung caused by inhalation of sterile gastric contents.

Epidemiology {#s0050}
============

An estimated 4 million cases of community‐acquired pneumonia (CAP) occur annually in the United States, accounting for at least 600,000 hospital admissions. CAP is the sixth leading cause of death. The mortality rate for hospitalized CAP patients is approximately 1 in 10 but this rate is higher in specific populations (e.g., nursing home residents) and approaches 40% in the severely ill who require admission to the intensive care unit.

Aspiration Pneumonia {#s0060}
--------------------

Aspiration pneumonia accounts for up to 15% of CAP cases and is common among nursing home residents. The risk of aspiration pneumonia is higher in the elderly and patients with dysphagia, stroke, or critical illness and lower in patients without teeth. Usually, the episode of aspiration is not witnessed; the diagnosis is inferred when patients at risk for aspiration present with an infiltrate in a characteristic pulmonary location (posterior upper lobe or apical lower lobe segments from recumbent aspiration, and basal lower lobe segments from upright or semi‐recumbent aspiration). Patients with aspiration pneumonia have clinical features similar to those of patients with CAP but have a higher incidence of pulmonary cavitation and abscess formation.

Early studies identified anaerobic organisms as the predominant pathogens in patients with aspiration pneumonia, but this has not been confirmed in recent studies.

Aspiration Pneumonitis {#s0070}
----------------------

Aspiration pneumonitis occurs in patients with altered consciousness (e.g., seizures, drug overdose, and anesthesia). The aspirated gastric contents are usually sterile but the acidity burns the lung, causing an intense inflammatory reaction. Bacterial infection may subsequently develop, but the prevalence of this complication is unknown. Infection likely plays some role if the gastric contents are colonized with pathogenic organisms (e.g., gastroparesis, enteral feedings, and ant‐acid therapy raise the gastric pH and increase the risk of bacterial colonization).

Aspiration pneumonitis has a broad spectrum of presentation, ranging from cough or wheeze to cyanosis, shortness of breath, hypoxemia, hypotension, acute respiratory distress syndrome, and death.

Causes of Community‐Acquired Pneumonia {#s0080}
--------------------------------------

Most cases of CAP are limited to a few key organisms ([Box 13‐1](#tbx0010){ref-type="boxed-text"} ), although in most cases the cause of the pneumonia is not identified. *S. pneumoniae* (pneumococcus) accounts for approximately two thirds of all cases of bacteremic pneumonia. Other common pathogens include *M. pneumoniae, C. pneumoniae*, and *Legionella* species, which have been reported to cause "atypical" pneumonia (pneumonia that does not present with classic signs and symptoms). In the past, the presenting signs and symptoms of pneumonia were thought to predict the causative agent, but we now know this to be untrue---there is a wide spectrum of presentation for each organism that is known to cause CAP, and these pathogens cannot be distinguished based only on symptoms, clinical signs, and findings on chest x‐ray.Box 13‐1Some Causative Agents of Community‐Acquired PneumoniaBacterial*Streptococcus pneumoniaeHaemophilus influenzaeMycoplasma pneumoniaeLegionella speciesChlamydia pneumoniaeChlamydia psittaciCoxiella burnetiiStaphylococcus aureusPseudomonas aeruginosa*Enteric gram‐negativesAnaerobesViralInfluenza virusRespiratory syncytial virusParainfluenza virusAdenovirusCoronavirusAdapted from File TM. Community‐acquired pneumonia. *Lancet.* 2003;362:1991--2001.

Symptoms and Signs {#s0090}
==================

Immunocompetent adults presenting with pneumonia may have fever (∼ 80%), cough (\> 90%), sputum production (∼ 66%), dyspnea (∼ 66%), and pleuritic chest pain (∼ 50%). However, these symptoms may also occur in patients with bronchitis or upper respiratory tract infections. Therefore, symptoms at presentation do not reliably distinguish between CAP and other respiratory illnesses. Bronchitis and upper respiratory tract infections are usually caused by viruses and can almost always be differentiated from pneumonia using chest x‐ray. One caveat is that the chest x‐ray may be normal in patients with CAP who are dehydrated. In this setting, the infiltrate should become visible following adequate hydration.

Extrapulmonary symptoms, including gastrointestinal symptoms, headache, myalgias, and arthralgias, occur in up to one third of CAP patients.

Physical exam findings depend on the severity of the infection. The patient may have fever, tachypnea, hypoxemia, pulmonary crackles, bronchial breath sounds, and respiratory distress with accessory respiratory muscle use.

Laboratory Data {#s0100}
---------------

Initial laboratory testing for patients with CAP requiring hospital admission should include:1Complete blood count (with differential) and chemistry panel, including assessment of renal function and glucose2Blood cultures (controversial; see following text)3PA and lateral chest x‐ray, which may show a lobar (occurring in one lobe of the lung) or segmental pulmonary infiltrate, patchy or diffuse lung infiltrates, or pleural effusion. The "air bronchogram sign" occurs when dense lung consolidation delineates air in the intrapulmonary bronchi, which are not normally visualized on chest x‐ray. This sign confirms the presence of lung consolidation. The chest x‐ray is also useful for ruling out complications, such as pneumothorax, abscesses, and empyema.4Sputum for gram stain and culture from a deep cough (controversial; see following text). If appropriate, also test the sputum for tuberculosis, *Legionella*, fungi, and viruses.5Assessment of arterial oxygenation (arterial blood gas or pulse oximetry)6Thoracentesis to rule out empyema if there is an effusion measuring \> 10 mm on lateral decubitus chest x‐ray

Other tests that may be appropriate (depending on the clinical circumstances) include:1Urine antigen assay for *L. pneumoniae* serogroup 1. This test is appropriate for (a) hospitalized patients with an unusual presentation of pneumonia, (b) patients with an unusual pneumonia admitted to the intensive care unit during a *Legionella* epidemic, and (c) patients who fail to respond to a beta‐lactam antibiotic.2Urine antigen assay for *S. pneumoniae*. This test can be used as an adjunct to blood and sputum cultures, with the potential advantage of a rapid turnaround time.

There is no well‐documented benefit for establishing the causative agent in CAP. Therefore, collection of blood and sputum samples in all CAP patients is controversial. Sputum samples are also limited by the ability of the patient to produce a good specimen and the experience of the person interpreting the Gram stain. Nonetheless, these samples may be useful for directing therapy if the patient fails to respond to empiric treatment. Ideally, sputum and blood samples should be collected prior to antibiotic administration, but antibiotic therapy should never be delayed because early treatment is important for the outcome of CAP.

Treatment {#s0110}
=========

Should the Patient with CAP be Admitted to the Hospital? {#s0120}
--------------------------------------------------------

If you are on the inpatient medicine service, this decision has already been made. However, you may be involved in the decision‐making process during a rotation through the emergency department or if you see a patient with CAP in clinic. Recognized risk factors for increased mortality in CAP include advanced age and co‐morbidities, such as cancer and heart failure. The decision to admit relies on clinical judgment, although there are also prognostic scoring rules that can support this decision. The most widely used and rigorously studied prediction rule is the Pneumonia PORT (Pneumonia Outcomes Research Team) Severity Index (PSI), which stratifies patients into one of five categories using a point system based on several variables at the time of presentation ([Fig. 13‐1](#f0010){ref-type="fig"} ). An easy‐to‐use version is available on the internet at [*http://ncemi.org*](http://ncemi.org). The higher the score, the higher the 30‐day mortality rates, the longer the length of stay, the higher the risk of admission to the intensive care unit, and the higher the risk of readmission to the hospital. The risk for death ranges from 0.1% to 2.8% for classes I to III, 8.2% to 9.3% for class IV, and 27% to 31% for class V. Therefore, the Infectious Diseases Society of America recommends home care for risk classes I to III only. Patients with low PORT scores may fail outpatient treatment because of preexisting conditions, such as social or psychiatric problems, inability to take oral medication, or acute hypoxemia. Therefore, an assessment for factors that may compromise successful outpatient therapy for CAP should occur prior to calculation of the PORT score. In other words, prediction rules might oversimplify the interpretation of important variables. Therefore, these scoring systems should not take the place of clinical judgment.Figure 13‐1Calculation of the Pneumonia PORT (Pneumonia Outcomes Research Team) Severity Index (PSI). Point Scoring System for Assignment to Risk Classes II, III, IV, and V (sum each applicable characteristic tocalculate the total score).**Age**MenAge (years)WomenAge (years) − 10**Nursing home resident+ 10Co‐morbidities** Neoplastic disease+ 30 Liver disease+ 20 Congestive heart failure+ 10 Cerebrovascular disease+ 10 Renal disease+ 10**Physical exam findings** Altered mental status+ 20 Respiratory rate ≥ 30/min+ 20 Systolic blood pressure \< 90 mm Hg+ 20 Temperature \< 35°C or ≥ 40°C+ 15 Pulse ≥ 125/min+ 10**Laboratory findings** Arterial pH \< 7.35+ 30 Blood urea nitrogen ≥ 11 mmol/L+ 20 Sodium \< 130 mmol/L+ 20 Glucose ≥ 250 mg/dL+ 10 Hematocrit \< 30%+ 10 pO~2~ \< 60 mm Hg or O~2~ sat \< 90%+ 10 Pleural effusion+ 10**Neoplastic disease** = any cancer (except basal‐ or squamous‐cell skin cancer) active at the time of presentation or diagnosed within 1 year of presentation**Liver disease** = clinical or histologic diagnosis of cirrhosis or other chronic liver disease.Stratification of Risk Score (based on the previous algorithms)Risk ClassTotal ScoreRecommended Site of TreatmentMortality Range (%)I0Outpatient0.1II≤ 70Outpatient0.6III71--90Outpatient0.9--2.8IV91--130Inpatient8.2--9.3V\> 130Inpatient27.0--29.2[^1]

Medications {#s0130}
-----------

### Drug‐Resistant S. pneumoniae {#s0140}

Drug‐resistant *S. pneumoniae* is on the rise---20% of *S. pneumoniae* are penicillin‐resistant and approximately one third are macrolide‐resistant. Fluoroquinolone resistance is low in the United States. Risk factors for penicillin and fluoroquinolone resistance are listed in [Box 13‐2](#tbx0020){ref-type="boxed-text"} .Box 13‐2Risk Factors for Drug‐Resistant Streptococcus pneumoniaePenicillin‐Resistance\*Age \> 65 yearsTreatment with a beta‐lactam within 3 monthsMedical co‐morbiditiesAlcoholismImmunosuppressionExposure to a child in a daycare centerLevofloxacin‐Resistance^†^Nursing home residentNosocomial infectionPrevious exposure to a fluoroquinoloneChronic obstructive pulmonary disease^\*^Adapted from File TM. Community‐acquired pneumonia. *Lancet*. 2003;362:1991‐2001. ^†^Adapted from Ho PL, et al. Risk factors for acquisition of levofloxacin‐resistant *Streptococcus pneumoniae:* a case control study. *Clin Infect Dis.* 2001;32:701--707.

Guidelines for Empiric Treatment {#s0150}
--------------------------------

The Infectious Diseases Society of America recommends a beta‐lactam plus a macrolide, or fluoroquinolone monotherapy for the empiric treatment of CAP requiring admission to the general medical ward ([Table 13‐1](#t0010){ref-type="table"} ). These regimens have been shown to reduce mortality when compared to cephalosporin monotherapy. Patients admitted to the intensive care unit with CAP should receive coverage for *S. pneumoniae, Legionella*, and possibly *Pseudomonas* (see [Table 13‐1](#t0010){ref-type="table"}). Risk factors for *Pseudomonas* infection include structural lung disease (e.g., bronchiectasis) and recent hospitalization (especially if the prior hospital stay included time in the intensive care unit).Table 13‐1Recommendations for Empirical Inpatient Treatment of Community‐Acquired Pneumonia for Patients Admitted to the Medical Ward and Intensive Care UnitExamples with Dosing[\*](#tn0010){ref-type="table-fn"}**Medical Ward**Anti‐pneumococcal fluoroquinoloneLevofloxacin 500 mg q24h OR gatifloxacin 400 mg q24h OR moxifloxacin 400 mg q24hβ‐lactam with macrolideCeftriaxone 1--2 g IV q24h OR cefotaxime 1--2 g IV q8h OR ampicillin/sulbactam 1.5--3 g IV q6hPLUSAzithromycin 500 mg IV q24h OR clarithromycin 250 mg PO q12hIntensive Care UnitIf pseudomonas is not a concern:**No beta‐lactam allergy:**β‐lactam plus macrolide or fluoroquinolone monotherapyCeftriaxone 1--2 g IV q24h OR cefotaxime 2 g IV q4--8h OR ampicillin/sulbactam 1.5--3 g IV q6h OR piperacillin/tazobactam 3.375 g IV q6hPLUSAzithromycin 500 mg IV q24h**Beta‐lactam allergy:**Levofloxacin 500 mg q24h± clindamycin 600 mg IV q8hIf pseudomonas is a concern**No beta‐lactam allergy:**(see text)Pipercillin/tazobactum 3.375 g IV q6h OR cefepime 1--2 g IV q12hANDAnti‐pseudomonal agent and anti‐pseudomonal fluoroquinoloneCiprofloxacin 400 mg IV q8--12h OR levofloxacin 500 mg q24h**Beta‐lactam allergy:**Aztreonam 1--2 g IV q6--12h AND levofloxacin 500 mg q24h[^2]Adapted with Permission from Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community‐acquired pneumonia in immunocompetent adults. *Clin Infect Dis*. 2003;37:1405--1433. Copyright © 2003 The University of Chicago Press and the Infectious Diseases Society of America.

Additional Recommendations Regarding Antibiotic Use {#s0160}
---------------------------------------------------

If a causative organism is identified based on sputum or blood sample results, the empiric antibiotic regimen should be switched to a narrow spectrum agent based on susceptibilities. This practice should reduce selective pressures for bacterial resistance.

The optimum duration of antibiotic administration is unknown, but most physicians treat for 7 to 10 days based on patient co‐morbidities and response to treatment. With appropriate antibiotic use, fevers will trend downwards but may take up to 72 hours to fully resolve. Persistent fevers or worsening clinical status should prompt an evaluation for worsening pneumonia (repeat chest x‐ray and possibly a CT scan) or complications, such as an empyema or metastatic infection (meningitis, septic arthritis, pericarditis, and peritonitis).

Therapy for Aspiration Pneumonitis {#s0170}
----------------------------------

After a witnessed aspiration event, the upper airway should be suctioned. Prophylactic antibiotics are frequently used but are generally not indicated (at least initially) in the majority of patients with aspiration pneumonitis because the antibiotics may select for resistant organisms in patients with uncomplicated chemical pneumonitis. Antibiotic therapy is appropriate if the aspiration pneumonitis does not resolve within 48 hours of the aspiration event or if the patient is likely to have bacterial colonization of the gastric contents (e.g., small bowel obstruction or use of antacids or proton pump inhibitors). In this setting, broad‐spectrum agents are recommended. Anaerobic coverage is not routinely needed. A reasonable treatment plan is levofloxacin 500 mg daily or intravenous ceftriaxone 1 to 2 g daily (dosages assume normal renal function). Glucocorticoids have no proven benefit.

Therapy for Aspiration Pneumonia {#s0180}
--------------------------------

Crude assessment of the cough and gag reflexes unreliably identifies patients at risk for aspiration. Rather, a comprehensive swallowing evaluation is required (preferably a swallow study with concurrent speech therapy evaluation). A soft diet should be started if swallowing dysfunction is detected and the patient should be taught strategies to lower the risk of aspiration, such as reducing the bite size, swallowing repeatedly, and keeping the chin tucked while eating.

Percutaneous endoscopic gastrostomy (PEG) tubes are no longer routinely used in patients at high‐risk for aspiration, because PEG tubes have not been shown to alter mortality in this population.

Antibiotics are standard of care for patients with aspiration pneumonia. Therapy should generally include activity against gram‐negative organisms. Levofloxacin 500 mg daily is a reasonable treatment option (dosage assumes normal renal function). Anaerobic coverage (e.g., IV clindamycin 600 mg three times daily or metronidazole 500 mg three times daily) should be added if there is a lung abscess, necrotizing pneumonia, severe periodontal disease, or putrid sputum.

When is the CAP Patient Ready for Discharge? {#s0190}
============================================

The Infectious Diseases Society of America recommends that the patient have no more than one of the following characteristics during the 24 hours preceding hospital discharge (unless this represents the patient\'s baseline status):1Temperature \> 37.8° C (\> 100° F)2Pulse \> 100 bpm3Respiratory rate \> 24 breaths / min4Systolic blood pressure \< 90 mm Hg5Blood oxygen saturation \< 90%6Inability to maintain oral intake

Pulmonary infiltrates may take up to several weeks or even months to fully resolve after successful treatment of CAP (especially in smokers, the elderly, and patients with underlying lung disease).

Prevention {#s0200}
==========

The following prevention measures should be addressed with every CAP patient:1Encourage smoking cessation, if applicable.2Administer the polysaccharide pneumococcal vaccine to:(a)Patients 65 years and older (redose if the person was vaccinated before the age of 65 years and 5 or more years have elapsed since the initial vaccination).(b)Patients younger than 65 years who live in a chronic care facility or who have a compromised immune system, diabetes mellitus, alcoholism, chronic pulmonary, liver, or cardiovascular disease (redose when the patient is over the age of 65 years and 5 or more years have elapsed since the initial vaccination).3Administer the inactivated influenza vaccine to:(a)Patients 50 years of age and older(b)Residents of chronic care facilities or patients with diabetes mellitus, immunosuppression, or chronic pulmonary, renal, or cardiovascular disease

The inactivated influenza vaccine can be given to patients with a minor respiratory illness but administration should be delayed in patients with acute febrile illness until symptoms have mostly resolved. Patients with a history of anaphylaxis to hens\' eggs should not be given the vaccine nor should those who developed Guillain‐Barré syndrome from a prior influenza vaccine.

[^1]: From Fine MJ, *et al*. A prediction rule to identify low‐risk patients with community‐acquired pneumonia. *N Engl J Med*. 1997;336:243--250. Copyright © 1997 Massachusetts Medical Society. All rights reserved. Adapted with permission, 2005.

[^2]: Dosages assume normal renal function. Fluoroquinolone dosages are IV or oral, unless otherwise indicated.
